Tilray Brands Inc vs Global X Uranium ETF — how do they compare? Tilray Brands Inc trades at $4.25 (market cap $524.07M), while Global X Uranium ETF trades at $40.37. The key difference: Global X Uranium ETF is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| TLRY | URA | |
|---|---|---|
Market Cap | $524.07M | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $21.00 | $61.81 |
52-Week Low | $4.23 | $36.45 |
Enterprise Value | $621.22M | — |
Signals from Pluang's Aura AI — not financial advice
TLRY trades at $4.23, down 1.63% on the day, with a bearish technical signal and negative earnings trends. The company reported a net loss of $2.19 billion in 2025 despite revenue growth to $821.31 million, reflecting deep profitability challenges. Analysts show cautious sentiment with 65% hold ratings, while recent news highlights expansion in medical cannabis and beverage segments amid ongoing regulatory uncertainty.
The outlook remains challenged by persistent losses and high debt-to-asset ratio of 12.25, though low P/S and P/B ratios suggest undervaluation. Key risks include profitability execution and federal cannabis policy shifts, while potential catalysts lie in international expansion and cost management improvements.
URA trades at $38.64, down 0.28% on the day, with technical indicators showing a bearish trend from moving averages but oversold RSI signals. The ETF holds $6.29 billion in assets and benefits from strong narratives around AI-driven power demand and nuclear energy expansion, though key financial ratios are not publicly detailed for the fund itself. Recent news highlights uranium's role in meeting data center electricity needs.
Outlook is supported by structural demand trends, but high expense ratios and competition from pure-play uranium funds pose risks. The fund's performance hinges on uranium price movements and policy developments, with current technical weakness suggesting caution in the near term.
Trailing returns across standard periods
Latest headlines on both assets
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →